June 6, 2018 10:19 AM EDT

Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX's door with an IPO application

Amber Tong

A month after the Hong Kong Stock Exchange opened its doors to pre-revenue biotechs — and received one guest, Ascletis — Hua Medicine has walked in with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX's door with an IPO application

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Eye­ing NDA for its di­a­betes drug, Hua Med­i­cine knocks at HKEX's door with an IPO ap­pli­ca­tion

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX's door with an IPO application